

Additional Table S1. Characteristics of patients with or without AKI.

Parameter	Cisplatin-induced AKI		P-value
	Yes (n=18)	No (n=66)	
Gender			
Male	13 (72.2%)	47 (71.2%)	
Female	5 (27.8%)	19 (28.8%)	0.56
Age (y)			
Median (Range)	63 (34-75)	60 (33-74)	0.48
ECOG performance status			
0 / 1 / 2	10 / 7 / 0	31 / 31 / 0	
3 / 4 / unknown	0 / 0 / 1	1 / 0 / 3	
Histology			
Small cell carcinoma	2 (11.1%)	17 (25.8%)	0.19
Adenocarcinoma	7 (38.9%)	30 (45.5%)	0.62
Large cell carcinoma	1 (5.6%)	1 (2%)	0.32
Squamous cell carcinoma	3 (16.7%)	10 (15.2%)	0.87
Malignant pleural mesothelioma	1 (5.6%)	5 (7.6%)	0.77
Thymic malignancy	0	2 (3%)	0.45
Others	4 (22.2%)	1 (2%)	0.001
Cisplatin			
Median dose (mg/m ² /day)	80 (60-80)	80 (40-80)	
Cycle Median (Range)	4 (1-6)	4 (1-6)	0.95
Anticancer drugs			
Vinorelbine	5 (27.8%)	21 (31.8%)	0.9
Etoposide	5 (27.8%)	9 (13.6%)	0.15
Docetaxel	2 (11.1%)	10 (15.2%)	0.66
Pemetrexed	1 (5.6%)	10 (15.2%)	0.29
Gemcitabine	2 (11.1%)	2 (3%)	0.16
S-1	2 (11.1%)	2 (3%)	0.16
Irinotecan	0	2 (3%)	0.46
Others	1 (5.6%)	10 (15.2%)	0.29
Serum Creatinine (mg/dl)			
Median (Range)	0.7 (0.5-1)	0.7 (0.5-1)	0.72
eGFR (mL/min/1.73m ²)			
Median (Range)	79.2 (59.2-101)	82.4 (60-113)	0.22
CKD risk factors			
Smoking	14 (77.8%)	55 (83.3%)	0.59
Hypertension	9 (50%)	20 (30.3%)	0.12
Dyslipidemia	6 (33.3%)	12 (18.2%)	0.17
Use of NSAIDs	7 (38.9%)	10 (15.2%)	0.04
Obesity	2 (11.1%)	13 (19.7%)	0.4
Diabetes mellitus	2 (11.1%)	8 (12.1%)	0.91
Hyperuricemia	2 (11.1%)	8 (12.1%)	0.95
Urinary tract stone	0	9 (13.6%)	0.12
Age ≥70	1 (5.6%)	7 (10.6%)	0.52
Cardiac disease	4 (22.2%)	3 (4.5%)	0.04
Hematuria	0	4 (6.1%)	0.29
Cerebrovascular disease	0	4 (6.1%)	0.29
Autoimmune disease	2 (11.1%)	2 (3%)	0.15
Proteinuria	0	1 (2%)	0.6
Infectious disease	0	0	-
Past history of ARF	0	0	-
Pt. with CKD risk	18 (100%)	62 (93.9%)	0.29
Pt. without CKD risk	0	4 (6.1%)	0.29
No. of CKD risk factors			
≤2	8 (44.4%)	36 (54.5%)	
3	3 (16.7%)	18 (27.3%)	0.72
4	4 (22.2%)	8 (12.1%)	0.69
≥5	3 (16.7%)	4 (6.1%)	0.09
Other risk factors			
PS ≥1	7 (38.9%)	32 (48.5%)	0.48
Alb <3.5g/dL	3 (16.7%)	14 (21.2%)	0.49
Age ≥70	1 (5.6%)	7 (10.6%)	0.52
Charlson Comorbidity Index			
Median (Range)	6 (2-9)	6 (2-10)	0.78